Understand the complete disease landscape and size global markets with real-world data. DRG’s Epidemiology cover 140+ diseases, 40+ countries, 3,400 patient segments, including extensive insights of oncology populations by stage, line of therapy, and biomarker. Learn more about DRG Epidemiology here.

The poster below was presented by DRG Epidemiologist Narendra Parihar, BDS, MPH, at ESMO International Congress on Targeted Anticancer Therapies (TAT) 2018, Paris, and projects the global forecast of prostate cancer drug-treatable populations eligible for targeted anticancer therapies for 2017-2027).

 

Author: DRG Epidemiologist Narendra Parihar, BDS, MPH

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now